Daratumumab / Hyaluronidase Injection

DRUG2 trials

Sponsors

Dartmouth-Hitchcock Medical Center, Eastern Cooperative Oncology Group

Conditions

Hemolytic AnemiaT-cell Acute Lymphoblastic Leukemia

Phase 1

The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia

CompletedNCT05004259

Dartmouth-Hitchcock Medical CenterHemolytic Anemia

Start: 2022-03-21End: 2024-09-21Updated: 2025-03-30

Phase 2

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

RecruitingNCT05289687

Eastern Cooperative Oncology GroupT-cell Acute Lymphoblastic Leukemia

Start: 2023-05-25End: 2027-06-30Target: 20Updated: 2026-09-15